1 / 5

Michael Roche PhD Student Burnet Institute

HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less efficient mechanism of gp-120 CCR5 engagement that attenuates macrophage tropism. Michael Roche PhD Student Burnet Institute. HIV Resistance to Maraviroc.

dermot
Download Presentation

Michael Roche PhD Student Burnet Institute

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less efficient mechanism of gp-120 CCR5 engagement that attenuates macrophage tropism Michael Roche PhD Student Burnet Institute

  2. HIV Resistance to Maraviroc • HIV uses CD4 as the primary receptor and either CCR5 or CXCR4 as a coreceptor for entry • Maraviroc (MVC) is the first approved drug in a new class of entry inhibitors – CCR5 antagonists • Bind and lock CCR5 in a conformation not recognized by HIV Env – allosteric inhibition • HIV can become resistant to MVC by emergence pre-existing CXCR4 using variants or by using the MVC modified form of CCR5 • Characterized by plateaus in inhibition (MPI) – non-competitive resistance • Is there an infectivity cost associated with using the MVC modified form of CCR5, such as changes in cell tropism? Competitive Resistance Non-competitive Resistance

  3. MVC attenuates Macrophage tropism of MVC resistant Env • MVC resistant Env from isolate generated in vitro • Characteristic resistant phenotype • High plateau – low level of resistance • Associated with a less efficient gp120-CCR5 interaction • Does this alter the cell tropism of the resistant virus? • MVC attenuates macrophage but not PBMC infection • Infectivity cost associated with resistance for this in vitro generated virus

  4. Level of MVC resistance in vivo is associated with the level of attenuation of Macrophage tropism by MVC • Envs cloned from 2 patients who failed MVC therapy with CCR5-using virus • Patient 17 displays high plateau, thus ‘very weak’ resistance • Patient 24 displays lowered plateau, thus ‘strong’ resistance • Level of resistance associates with attenuation of macrophage infection by MVC Patient 17 ‘Very Weak’ Resistance Patient 24 ‘Strong’ Resistance Conclusion: Maintaining MVC despite the development of resistance (in some cases) may spare the macrophage reservoir from infection and thus may have some clinical benefit

  5. Acknowledgments Pfizer Ltd Mike Westby Becky Jubb UCLA Benhur Lee Fillipo Posta Gorry Lab Paul Gorry Melissa Churchill Jasminka Sterjovski Anne Ellett Miranda Moore Hamid Salimiseyedabad Martin Jakobsen Kieran Cashin Lachlan Gray Daniel Cowley Paul Ramsland Sharon Lewin

More Related